Application and Precautions of CD20 Antibody Reagent (Immunohistochemistry) in Lymphoma Diagnosis

Clinical Significance of CD20 Detection

CD20 is a transmembrane protein expressed on the surface of mature B lymphocytes and plays an important role in B-cell development, activation, and antibody production. In histopathological diagnosis of lymphoid tissues, CD20 antibody reagent (immunohistochemistry method) is mainly used to assist in differentiating B-cell-derived lymphomas from T-cell-derived lymphomas, and can also be used to evaluate the immunophenotype of certain B-cell lymphomas. Common B-cell neoplasms such as diffuse large B-cell lymphoma, follicular lymphoma, and small lymphocytic lymphoma are typically CD20-positive, whereas T-cell lymphomas and Reed-Sternberg cells in Hodgkin lymphoma are often negative or weakly positive. Therefore, this reagent has important reference value for lymphoma classification, treatment regimen selection, and prognosis assessment.

Detection Principle and Experimental Procedure

The immunohistochemistry method is based on the principle of specific antigen-antibody binding. After deparaffinization and antigen retrieval, sections are incubated with CD20 primary antibody, followed by enzyme-labeled secondary antibody and chromogenic substrate to form a visible precipitate, thereby displaying the distribution of CD20 antigen in situ within the tissue. Currently, common primary antibody clones include L26, etc., which are generally suitable for paraffin-embedded tissue sections, and some clones can also be used for frozen sections. The experimental procedure typically includes baking, deparaffinization, hydration, antigen retrieval, blocking of endogenous peroxidase, primary antibody incubation, secondary antibody incubation, DAB chromogenic development, counterstaining, dehydration, and mounting. Antigen retrieval methods may include heat-induced retrieval (such as citrate buffer or EDTA buffer), and specific parameters should be optimized according to the reagent instructions.

Interpretation Criteria and Common Influencing Factors

CD20-positive signals are generally localized to the cell membrane, appearing brownish-yellow or brown, and staining intensity can be classified as weak, moderate, or strong. Interpretation should be combined with positive and negative controls; if controls do not meet expectations, the results should be considered invalid. Common influencing factors include insufficient or excessive tissue fixation time, inadequate antigen retrieval, inappropriate antibody concentration, and excessive chromogenic development time, all of which may lead to false negatives or false positives. For patients with recurrence after radiotherapy or chemotherapy, tumor cells may undergo immunophenotypic changes with reduced or absent CD20 expression; in such cases, comprehensive assessment should be combined with other B-cell markers (such as CD79a, PAX5).

Usage Specifications and Quality Assurance

CD20 antibody reagent (immunohistochemistry method) falls under the category of in vitro diagnostic reagents. Laboratories should strictly follow relevant regulations for medical devices/in vitro diagnostic reagents to perform performance verification, including precision, sensitivity, specificity, and lot-to-lot consistency. Parallel comparison should be conducted before introducing new reagent lots, and positive control tissue (such as tonsil) and negative controls should be set up for routine testing. Operators should receive standardized training, record experimental conditions and environmental data, and ensure traceability and reproducibility of results.